272
views
0
recommends
+1 Recommend
1 collections
    1
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      IP opportunities in drug repurposing

      Published
      proceedings-article
      1 , 1 , 1
      ScienceOpen
      RExPO22
      2-3 September, 2022
      Drug, pharmaceutical, repurposing, patent, medical use, protection, clinical trial, strategy, Europe, purpose-limited product claim
      Bookmark

            Abstract

            Drug repurposing – the strategy for developing a new clinical application of a known investigational drug or drug approved for a different indication – bears high potential for patients. Even in cases where the drug compound already underwent extensive clinical investigation, repurposing such a drug will still involve significant investments. For example, clinical trials relating to the new indication are to be conducted. One way to secure investments in the development of a new indication, is to seek patent protection. Patent protection may be particularly important in situations where regulatory exclusivity periods will be limited. In many jurisdictions around the world, so-called further medical uses of a known drug can be patented. These possibilities are not limited to applications in a truly different therapeutic area; in general, the application of a drug for a new sub-indication, the treatment of a new patient group (including stratification) and/or new therapeutic regimens may be subject to patent protection, although there are significant differences across jurisdictions as to what is possible exactly. Patents for such medical use inventions can be based on any type of supporting data. In those situations where clinical trial data is needed, timing is of the essence, given that clinical trial protocols typically enter the public domain before results actually become available. Patent systems around the world accommodate for the intrinsic difficulties associated with (clinical) drug development. In order to make use of the possibilities in an optimal way it is essential to think of the patenting strategy early on in the process. Ideally, the patenting strategy is already part of the pre-clinical development phase and certainly factors into the preparations for first in man trials, including clinical trial protocol drafting.

            Content

            Author and article information

            Conference
            ScienceOpen
            18 August 2022
            Affiliations
            [1 ] NLO, The Netherlands
            Article
            10.14293/S2199-rexpo22005.v1
            fd6f4d9c-71e9-4284-918c-969aae6d55d5
            The Authors

            Published under Creative Commons Attribution 4.0 International ( CC BY 4.0). Users are allowed to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source.

            RExPO22
            Maastricht, Netherlands
            2-3 September, 2022
            History

            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            patent,purpose-limited product claim,Europe,strategy,clinical trial,protection,medical use,repurposing,pharmaceutical,Drug

            Comments

            Comment on this article